The Company is investigating the health effects of various natural remedies on the health of consumers either alone or in conjunction with other elements.
In focus are various plant based products that are targeted to relieve symptoms such as:
- Chronic inflammation
- High Cholesterol
Initial projects will include Astaxanthin, Spirulina and eventually Cannabinoids.
Astaxanthin is a reddish pigment that belongs to a group of chemicals called carotenoids. It occurs naturally in certain algae and causes the pink or red color in salmon, trout, lobster, shrimp, and other seafood.
Astaxanthin is taken by mouth for treating oxidative stress on the heart and blood vessels, the support of joint and tendon health, the support of skin health from sun exposure, supports healthy vision and normal eye function and supports the body’s normal inflammatory response after strenuous exercise.
Astaxanthin is applied directly to the skin to protect against sunburn, to reduce wrinkles, and for other cosmetic benefits.
In food, it may be used as a feed supplement and food coloring additive for salmon, crabs, shrimp, chicken, and egg production.
How does it work?
Astaxanthin is an antioxidant. This effect might protect cells from damage. Astaxanthin might also improve the way the immune system functions.
As an ecologically sound, nutrient-rich, dietary supplement, spirulina is being investigated to address food security and malnutrition, and as dietary support in long-term space flight or Mars missions. Its interest for food security is for lower land and water needs to produce protein and energy than required for livestock as meat sources
Provided in its typical supplement form as a dried powder, a 100-g amount of spirulina supplies 290 Calories and is a rich source (20% or more of the Daily Value, DV) of numerous essential nutrients, particularly protein, B vitamins (thiamin and riboflavin, 207% and 306% DV, respectively), and dietary minerals, such as iron(219% DV) and manganese (90% DV).
A cannabinoid is one of a class of diverse chemical compounds that acts on cannabinoid receptors in cells that alter neurotransmitter release in the brain. Ligands for these receptor proteins include the endocannabinoids (produced naturally in the body by animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (manufactured artificially). The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis.
Cannabidiol (abbreviated as: CBD) is one of at least 113 cannabinoids identified in cannabis. It is a major phytocannabinoid, accounting for up to 40% of the plant’s extract. CBD does not appear to have any psychoactive effects such as those caused by tetrahydrocannabinol (THC). It may have a down regulating impact on disordered thinking and anxiety. Potential uses are the subject of ongoing research.
Pain associated with multiple sclerosis
Nabiximols (USAN, trade name Sativex) is an aerosolized mist for oral administration containing a near 1:1 ratio of CBD and THC. The drug was approved by Canadian authorities in 2005 to alleviate pain associated with multiple sclerosis.
Two systematic review on CBD and addiction reported beneficial effects for alleviating tobacco and cannabis dependence. The anti-addictive properties displayed might be due to CBD’s protective effect on stress and neurotoxicity. Both reviews recommended more research.
Two reviews address research on the theory that CBD alone or in combination with THC may have anti-oxidant and anti-inflammatory activity. Neither cited any human trials.
Anecdotal reports and early studies suggested that CBD may be of value in treating epilepsy, but the quality of the studies was too poor to draw definitive conclusions. A 2014 Cochrane review included four randomized controlled trials, but all were of poor quality. A double-blinded, randomized, placebo-controlled study of CBD oil on treating Dravet syndrome, a rare form of epilepsy that begins in infancy and is difficult to treat, was conducted in 2017 and found that CBD oil significantly reduced the number of seizures with a dosing of 20mg/kg. However, it also caused increased diarrhea, vomiting, fevers, fatigue, abnormal liver function tests (LFTs), and somnolence. The LFTs showed elevated ALT and AST up to three times of normal, but only in the patients also taking valproate. The study already suggests that this might be an interaction of valproate and CBD. The abnormal LFT normalized during the trial in the patients who kept taking CBD.
GW Pharmaceuticals is seeking FDA approval to market a liquid formulation of pure plant-derived CBD, under the trade name Epidiolex (containing 99% cannabidiol and less than 0.10% Δ9-THC) as a treatment for Dravet syndrome. Epidiolex was granted fast-track status and orphan drug status in the United States for treatment of Dravet syndrome in July 2015.